Witty worked to remake GSK’s image. Greater access to drugs became ... Since the assassination of his top lieutenant Brian ...

GlaxoSmithKline’s (GSK) former chief executive Andrew Witty was yesterday announced as the new CEO of Optum – a US payer organisation which includes pharmacy benefits manager OptumRx.

GlaxoSmithKline (GSK) has announced it is to begin searching for a successor to CEO Andrew Witty, who will retire in just over a year's time. Witty has told GSK's board that he intends to retire ...

British drugmaker GlaxoSmithKline said today that chief executive Andrew Witty will retire in 2017 after almost 10 years at the helm. Witty, a 31-year company veteran, has been under fire from ...

Following the announcement, GSK Chief Executive Andrew Witty said: "As part of our strategy to grow and diversify GSK's business, we are continuing to make new investments through targeted ...

UnitedHealth Group CEO Andrew Witty’s compensation in 2024 declined 34% to $16.4 million. During 2024, the company’s stock had a return of -2.4%, which led several of its executives to postpone ...